News
XBI
97.51
-0.03%
-0.03
Notable ETF Outflow Detected - XBI, EXAS, SRPT, UTHR
NASDAQ · 2d ago
Small-cap stocks are perking up. Here’s how to pick winners. 
MarketWatch · 3d ago
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report
Regeneron Pharmaceuticals, Inc. (REGN) is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1. The company is expected to report a profit of $8.89 per share. REGN reported Q1 earnings on May 2. The stock is up 23.6% on a YTD basis.
Barchart · 3d ago
HQH: Discount Remains Attractive With A Now Higher Distribution Rate
Abrdn Healthcare Investors Fund focuses on the more cyclical biotech space, with over half of its portfolio allocated there. The fund's managed distribution policy was increased significantly since our prior update. The abrdn healthcare investors fund continues to trade at an attractive discount. Discount Narrows With Distribution Increase But Remains Appealing.
Seeking Alpha · 4d ago
ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors
Seeking Alpha · 4d ago
How The Pieces Add Up: XBI Targets $140
NASDAQ · 5d ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
NASDAQ · 5d ago
Weekly Report: what happened at XBI last week (0708-0712)?
Weekly Report · 6d ago
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
NASDAQ · 07/12 10:20
Notable ETF Inflow Detected - XBI, SRPT, UTHR, ALNY
NASDAQ · 07/11 14:50
Neuralink to implant brain device in second patient within weeks
Elon Musk's Neuralink to implant brain device in second patient within weeks. The company implanted its brain-computer interface device in its first patient earlier this year. The recipient is quadriplegic and uses the device to read and play video games. Musk says the company hopes to implant the device in a second patient in the next few weeks.
Seeking Alpha · 07/10 22:18
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and the Fed is expected to cut rates in September. The second half of 2024 holds potential for biotech stocks to break out of their consolidation.
Seeking Alpha · 07/09 11:00
Surprising Analyst 12-Month Target For XBI
NASDAQ · 07/08 14:23
Weekly Report: what happened at XBI last week (0701-0705)?
Weekly Report · 07/08 10:24
Global Anti-Obesity Market Analysis: Key Trends And Insights
Seeking Alpha · 07/04 15:30
SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts?
TipRanks · 07/04 13:05
How To Pick Top Pharma Stocks: Novo Nordisk And More
Nine steps I use to identify the most promising pharmaceutical companies and avoid pitfalls. Novo Nordisk is a leader in the fast-growing anti-obesity medicines market. The company has been approved in China to treat people living with obesity. This article includes an analysis of the company and its portfolio of product candidates. The author outlines his methodology for selecting pharmaceutical companies.
Seeking Alpha · 07/02 15:20
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
The technology sector led the 11 S&P 500 sectors in performance last month, surging 7.7%. The Utilities Select Sector SPDR Fund dropped 6.3%, marking the worst month since September 2023. The iShares Expanded Tech-Software Sector ETF rallied 11.3% last month. The S&p 500 gained 3.2% in June.
Benzinga · 07/01 17:38
IBB, XBI: 2 BioTech ETFs with Massive Upside, According to Analysts
TipRanks · 07/01 11:44
Weekly Report: what happened at XBI last week (0624-0628)?
Weekly Report · 07/01 10:25
More
Webull provides a variety of real-time XBI stock news. You can receive the latest news about SPDR® S&P Biotech ETF through multiple platforms. This information may help you make smarter investment decisions.